According to the Zhitong Finance App, Insili Intelligence (03696.HK) announced that the first human phase I clinical trial data of ISM6331, an innovative pan-TEAD inhibitor driven by artificial intelligence, has been received by the 2026 European Society of Medical Oncology (ESMO) Annual Meeting and made a brief oral presentation (Oral Rapid Oral Presentation).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.